Altamira Therapeutics is active in RNA therapeutics, allergy and viral infections, and inner ear disorders.
Location: United Kingdom, England, Eastbourne
Employees: 11-50
Total raised: $50.96M
Founded date: 2003
Investors 4
| Date | Name | Website |
| - | Idinvest P... | idinvest.c... |
| - | Hercules C... | htgc.com |
| - | Sofinnova ... | sofinnova.... |
| - | Kurma Part... | kurmapartn... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.04.2013 | Series C | $50.96M | Sofinnova ... |
Mentions in press and media 19
| Date | Title | Description |
| 26.05.2023 | Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis | Bentrio® meets primary efficacy endpoint in NASAR clinical trial in seasonal allergic rhinitis Clinically relevant and statistically significant improvement in Total Nasal Symptom Score over saline nasal spray control (p = 0.012) Bentrio ef... |
| 28.06.2021 | Auris Medical : Altamira Auris Medical Company Presentation Juni 2021 | Company Presentation June 2021 Forward-looking statements This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the... |
| 10.06.2021 | AURIS MEDICAL HOLDING LTD. Auris Medical : Corporate Presentation June 2021 | Company Presentation 2021 LD Micro Invitational XI - June 9, 2021 Forward-looking Statements This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities... |
| 03.06.2021 | AURIS MEDICAL HOLDING LTD. Auris Medical : Business Update June 2021 | Acquisition of Trasir Therapeutics Strategic Repositioning Business Update - June 3, 2021 Forward-looking Statements This presentation may contain statements that constitute "forward-looking statements" within the meaning of Secti... |
| 03.05.2021 | AURIS MEDICAL HOLDING LTD. Auris Medical : Corporate Presentation May 2021 | Innovative Treatments in Neurotology, Rhinology and Allergy and CNS Disorders Corporate Presentation May 2021 NASDAQ: EARS | Contact: [email protected] Forward-looking Statements This presentation may contain statements that consti... |
| 28.07.2017 | A race is underway to repair our hearing — with medicine | On any bustling city street, in the middle of the afternoon, it’s probably the case that half or more people are wearing earbuds, while the rest are abiding the noise pollution all around them. No one thinks twice about it, either. The real... |
| 22.02.2017 | PhRMA chief plays favorites in singling out Martin Shkreli as a ‘bad actor’; Roche extends antibiotics collaboration | → PhRMA CEO Steve Ubl enjoys holding up Turing’s Martin Shkreli as an example of the kind of “bad actors” that are giving pharma companies a bad name. The Boston Business Journal noted that Ubl singled out Shkreli in a Q&am... |
| 26.09.2016 | Can a Pill Fix Your Hearing? | Listen up, baby boomers (and others): Your damaged hearing may soon be improved—and it won’t require inserting a beige gizmo in your ear. Advances in molecular biology and bioinformatics have led to an explosion of research on the causes of... |
| 06.08.2014 | Auris Medical shares will be traded at NASDAQ as of today | |
| 22.07.2014 | Auris Medical Holding in den USA an die Börse |
Show more